Istradefylline

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 291 publications

Adenosine A2A receptors in the chorioid plexus are causal in mediating the development of hydrocephalus.

Adenosine A2A receptors in the chorioid plexus are causal in mediating the development of hydrocephalus.

Journal: Purinergic signalling

Published: March 15, 2026

Expanding Clinical Experience With Istradefylline in ADCY5-Related Movement Disorder: A Case With No Benefit.

Expanding Clinical Experience With Istradefylline in ADCY5-Related Movement Disorder: A Case With No Benefit.

Journal: Movement disorders clinical practice

Published: February 02, 2026

Caffeine Mitigates Adenosine-Mediated Angiogenic Properties of Choroidal Endothelial Cells Through Antagonism of A1 Adenosine Receptor and PI3K-AKT Axis.

Caffeine Mitigates Adenosine-Mediated Angiogenic Properties of Choroidal Endothelial Cells Through Antagonism of A1 Adenosine Receptor and PI3K-AKT Axis.

Journal: Cells

Published: December 10, 2025

High-throughput screening for the discovery of antidepressants targeting adenosine A2A receptors.

High-throughput screening for the discovery of antidepressants targeting adenosine A2A receptors.

Journal: Bioorganic chemistry

Published: November 26, 2025

Adenosine A₂A receptor as a dual-acting molecular switch: Glial morphological changes and neurovascular tissue remodeling in neuroinflammation and neurodegeneration.

Adenosine A₂A receptor as a dual-acting molecular switch: Glial morphological changes and neurovascular tissue remodeling in neuroinflammation and neurodegeneration.

Journal: Tissue & cell

Published: November 24, 2025

Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice.

Involvement of Adenosine A2A Receptors in Anxiety-Like Behaviors in Tetrahydrocannabinol-Treated Mice.

Journal: Brain and behavior

Published: November 18, 2025

Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model.

Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model.

Journal: Neurochemistry international

Published: November 17, 2025

Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study.

Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study.

Journal: Parkinsonism & related disorders

Published: October 28, 2025

Treatment strategies for motor fluctuations in Parkinson's disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America.

Treatment strategies for motor fluctuations in Parkinson's disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America.

Journal: Frontiers in pharmacology

Published: October 14, 2025

Intrathecal delivery of AAVrh10-mHexa combined with anti-inflammatory treatment reduces neuropathological markers and extends the lifespan of mice with early-onset Tay-Sachs disease.

Intrathecal delivery of AAVrh10-mHexa combined with anti-inflammatory treatment reduces neuropathological markers and extends the lifespan of mice with early-onset Tay-Sachs disease.

Journal: Metabolic brain disease

Published: September 26, 2025

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Journal: Molecular pharmaceutics

Published: September 07, 2025

The persisting puzzle of OFF time in advanced Parkinson's disease.

The persisting puzzle of OFF time in advanced Parkinson's disease.

Journal: Brain : a journal of neurology

Published: August 25, 2025

Showing 1-12 of 291

Last Updated: 04/28/2026